NuSight Medical introduced new device for dry eye treatment

Ophthalmic care company NuSight Medical has introduced a new medical device called the NuLids System to treat dry eyes.

Free Report

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.

By GlobalData

By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Unveiled at the American Optometric Association meeting in Denver, NuLids is said to improve dry eye conditions by gently stimulating and rejuvenating the Meibomian glands in the eye.

NuSight Medical president and CEO Rob Foster said: “Patients benefit from improved tear film stability, comfort, and lubrication that combat dry eye. Doctors gain an important therapy while helping to build their practice.

“The company stated that under the NuLids I and NuLids II clinical studies, nearly 95% of patients surveyed following a 30-day trial were said to be satisfied or very satisfied with the treatment.”

“And, because NuLids is sold only through licensed eye care practitioners, doctors are in control of the therapy while patients perform the treatment at home, improving practice efficiency.”

NuSight Medical founder and chairman John Olkowski said that nearly 86% of dry eye patients’ Meibomian gland function are damaged leading to unstable tear film and its premature breakdown.

The NuLids facilitates the production and flow of meibum at the gland reducing signs of dry eye.

At a clinical study, the NuLids System bettered Tear Breakup Time by 65%, while Meibomian Glands Yielding Liquid Secretions improved by 81%.

Most of the patients in the study also reported significant improvement in their dry eye conditions following two weeks of daily usage.

Taking around one minute per day, the NuLids process can be carried out with the in-office procedures performed by eye doctors.

NuSight claimed that the NuLids system is convenient to use without any known side effects.

The company also stated that under the NuLids I and NuLids II clinical studies, nearly 95% of patients surveyed following a 30-day trial were said to be satisfied or very satisfied with the treatment.